GlassScriptPhysician profile
Lola C Morgan
NPI 1487682100
$1,295.44
in general payments reported to CMS, 2019-2025
15 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2021: $29.53 · 2022: $263 · 2023: $397 · 2024: $181 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $256.14 | 2022-2023 | Valtoco |
| Sk Life Science, INC. | $242.34 | 2022-2023 | Xcopri |
| Otter Pharmaceuticals, LLC | $199.54 | 2024-2025 | Sympazan |
| Biogen, INC. | $125.74 | 2019 | |
| Immedica Pharma US, INC. | $124.99 | 2024 | |
| Eisai INC. | $124.99 | 2019 | |
| Ucb, INC. | $77.25 | 2022-2023 | Briviact |
| Aquestive Therapeutics, INC. | $40.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $32.84 | 2023 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $27.91 | 2023 | |
| Paratek Pharmaceuticals, INC. | $20.01 | 2024 | Nuzyra |
| Zogenix INC. | $12.60 | 2021 | |
| Aucta Pharmaceuticals, INC. | $10.75 | 2024 | Motpoly Xr |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lola Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.